CALIDI BIOTHERAPEUTICS, INC. - Common stock, par value $0.0001 per share (CLDI)

CUSIP: 320703309

Q4 2024 13F Holders as of 31 Dec 2024

Holder snapshot 6 signals
Share change
+783,458
SEC-reported price per share
$1.15
Number of holders
33
Value change
+$901,052
Number of buys
26
Number of sells
5
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
11,128,448

Security key

320703309

Report period

Q4 2024

Institutions

33

Top holders

10

Ownership snapshot

Top reported holders of CLDI - CALIDI BIOTHERAPEUTICS, INC. - Common stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Polar Asset Management Pa...
Disclosed value leader
Polar Asset Management Pa...
Comparable rows
0/15
Latest evidence
30 Sep 2024
3/4/5 13F Highest disclosed value: $4,330,272 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Polar Asset Management Partners Inc. has the largest disclosed position value at $4.33M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Polar Asset Management Partners Inc.'s linked filing trail.
Disclosed position value Top 5
Polar Asset Management Partners Inc. $4.33M
Stephen Thesing $848.8K
Boris Radoslavov Minev $764K
Thomas A. Vecchiolla $657.2K
Tony T. Kalajian $501.8K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Polar Asset Management Partners Inc.
3/4/5 13F
10%+ Owner · Company
—
denominator unverified
$4,330,272
412,800 shares
— 19 Oct 2022
First Light Acquisition Group, LLC
3/4/5
10%+ Owner
—
denominator unverified
—
1,931,852 shares
— 16 Jun 2023
Stephen Thesing
3/4/5
Chief Business Officer
—
denominator unverified
$848,779
471,544 shares
— 12 Sep 2023
Boris Radoslavov Minev
3/4/5
Interim Chief Medical Officer
—
mixed-class rows
$764,024
455,818 shares
mixed-class rows
— 17 Jun 2024
Thomas A. Vecchiolla
3/4/5
Director
—
mixed-class rows
$657,189
781,459 shares
mixed-class rows
— 21 Dec 2023
Tony T. Kalajian
3/4/5
Chief Acctg Officer, Int. CFO
—
denominator unverified
$501,822
278,790 shares
— 12 Sep 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
33
Shares
1,102,228
Rows available
33
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2024 vs Q3 2025 Across Filers

Q3 2025 holders
2
Q4 2024 holders
33
Holder diff
31
Investor Q3 2025 Shares Q4 2024 Shares Share Diff Share Chg % Q3 2025 value Q4 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .